MAPT and Alzheimer disease: Extensive preclinical research has demonstrated that naringenin modulates critical pathways involved in AD progression, including amyloid‐β (Aβ) deposition, tau hyperphosphorylation, oxidative stress, neuroinflammation, and synaptic dysfunction.